Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis
By Colin Kellaher
Johnson & Johnson has won U.S. Food and Drug Administration approval of its Icotyde treatment for certain patients with moderate-to-severe plaque psoriasis, a chronic autoimmune condition that causes itchy, painful skin patches.
J&J on Wednesday said the approval covers Icotyde in adults and pediatric patients 12 years of age and older who weigh at least 40 kilograms who are candidates for systemic therapy or phototherapy.
The New Brunswick, N.J., healthcare giant said the green light makes Icotyde the first and only approved targeted oral peptide that precisely blocks the interleukin-23 receptor, which contributes to the inflammatory process of several inflammatory autoimmune disorders.
J&J is developing Icotyde as part of a 2017 partnership with Protagonist Therapeutics and has the exclusive rights to commercialize the drug.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 18, 2026 09:16 ET (13:16 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States